Please login to the form below

Not currently logged in
Email:
Password:

Biogen-Samsung

This page shows the latest Biogen-Samsung news and features for those working in and with pharma, biotech and healthcare.

Pfizer closes on EU approval of lung cancer drug Vizimpro

Pfizer closes on EU approval of lung cancer drug Vizimpro

The two new biosimilars will join products from Amgen, Samsung Bioepis/Biogen, Mylan/Fujifilm Kyowa Kirin, and Novartis’ Sandoz unit in an assault on AbbVie’s market share for the

Latest news

More from news
Approximately 3 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Samsung Bioepis is a joint venture between Samsung and Biogen Idec; the latter recently (June 2018) invested $700m to bring its stake in the jv to 49.9%. ... Merck &Co has paid $155m to Samsung Bioepis to cover the investments made so far, plus interest,

  • An eye towards the biobetter in South Korea An eye towards the biobetter in South Korea

    SAIT101. Samsung Bioepis. Biogen Idec. NHL. S Korea. Phase I started in Mar 2011. ... This is because only larger entities like Samsung Bioepis and Hanwha Chemical have sufficient resources to absorb the financial risks of failed trials.

  • Pharma deals during February 2013 Pharma deals during February 2013

    time Merck is not going it alone, but has announced a collaboration with Samsung Bioepis (the joint venture between Samsung and Biogen Idec set up in December 2011. ... Samsung Bioepis will be responsible for all the development work, whilst Merck gains

  • Pharma deals during July 2012 Pharma deals during July 2012

    Two weeks prior to the announcement of the collaboration between Amgen and Watson, Biogen Idec and Samsung Biologics announced the establishment of a $300m joint venture to develop and commercialise biosimilars. ... With these developments, there is the

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics